<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513171</url>
  </required_header>
  <id_info>
    <org_study_id>TB1805GH</org_study_id>
    <nct_id>NCT04513171</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children</brief_title>
  <official_title>A Multi-center, Randomized, Positive-control, Phase 2&amp;3 Combined Study of Y-shape Pegylated Somatropin in Prepubertal Children With Growth Hormone Deficiency.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen Amoytop Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen Amoytop Biotech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-labeled, positive controlled phase 2&amp;3 combined study&#xD;
      to evaluate the safety and efficacy of weekly Y-shape pegylated somatropin, compared to daily&#xD;
      somatropin (Norditropin®), in prepubertal, treatment-naive children with growth hormone&#xD;
      deficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter, randomized, open-labeled, positive controlled study is divided into two&#xD;
      stages. The first one is aimed to exploit the optimal dose of Y-shape pegylated somatropin,&#xD;
      while the second one is aimed to confirm the efficacy and safety of the study drug. A total&#xD;
      of 400 prepubertal children with growth hormone deficiency were expected to enrolled.&#xD;
      Subjects will firstly undergo a 52 weeks treatment, and then followed for 5 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 2: Change of areas under the curve of IGF-1 concentration from baseline (ΔIGF-1 AUC).</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 3: Change of annualized height velocity from baseline.</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of height standard deviation score according to chronological age.</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of height standard deviation score according to bone age.</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IGF-l level</measure>
    <time_frame>change from baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IGFBP-3 level</measure>
    <time_frame>change from baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>Y-shape pegylated somatropin low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Y-shape pegylated somatropin middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Y-shape pegylated somatropin high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Norditropin-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Y-shape pegylated somatropin optimal dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Norditropin-2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Y-shape pegylated somatropin</intervention_name>
    <description>Y-shape pegylated somatropin 100μg/kg, subcutaneous injection, Once weekly.</description>
    <arm_group_label>Y-shape pegylated somatropin low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Y-shape pegylated somatropin</intervention_name>
    <description>Y-shape pegylated somatropin 120μg/kg, subcutaneous injection, Once weekly.</description>
    <arm_group_label>Y-shape pegylated somatropin middle dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Y-shape pegylated somatropin</intervention_name>
    <description>Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.</description>
    <arm_group_label>Y-shape pegylated somatropin high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norditropin®</intervention_name>
    <description>Norditropin 245μg/kg/week, subcutaneous injection, Once daily.</description>
    <arm_group_label>Norditropin-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Y-shape pegylated somatropin</intervention_name>
    <description>Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.</description>
    <arm_group_label>Y-shape pegylated somatropin optimal dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norditropin</intervention_name>
    <description>Norditropin 245μg/kg/week, subcutaneous injection, Once daily.</description>
    <arm_group_label>Norditropin-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of GHD confirmed by two different GH stimulation tests, defined as a peak of&#xD;
             GH level of &lt;10.0 ng/ml, determined with a validated assay. Bone age (BA) at least 2&#xD;
             years less than the chronological age. Growth velocity less than 5.0 cm/year. Impaired&#xD;
             HT defined as at least 2.0 standard deviations (SD) below of the mean height for&#xD;
             chronological age and sex (HT SDS&lt;-2.0).&#xD;
&#xD;
          -  Prepubertal (Tanner Ⅰ) males and females by physical examination, aged older than 3&#xD;
             years and younger than10 years for girls and 11 years for boys.&#xD;
&#xD;
          -  Short stature with normal intelligence.&#xD;
&#xD;
          -  Baseline IGF-1 level below the median IGF-1 level standardized for age and sex.&#xD;
&#xD;
          -  Written, signed informed consent of the parent(s) or legal guardian(s) of the subject&#xD;
             and written assent of the subject (if the subject is 8 years old or above).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to growth promotion treatment, such as recombinant human growth hormone&#xD;
             or gonadal hormones, for more than 1 month.&#xD;
&#xD;
          -  Known hypersensitivity to somatropin or excipients, such as mannitol, lysine, sodium&#xD;
             chloride.&#xD;
&#xD;
          -  Children with closed epiphyses.&#xD;
&#xD;
          -  Short stature etiologies other than GHD, such as idiopathic short stature, Turner&#xD;
             syndrome, Prader-Willi syndrome, Russell-Silver syndrome, born small for gestational&#xD;
             age regardless of GH status.&#xD;
&#xD;
          -  Other causes of short stature such as hypothyroidism, adrenocortical hormone&#xD;
             deficiency, antidiuretic hormone deficiency.&#xD;
&#xD;
          -  Any medical conditions and/or presence that may affect growth velocity such as liver&#xD;
             dysfunction, kidney dysfunction, malnutrition, diabetes mellitus, severe dysfunction&#xD;
             in major organ such as heart, sever systemic infections, severe immune dysfunction,&#xD;
             mental disorders, and other congenital malformations.&#xD;
&#xD;
          -  Suffering from chronic infectious diseases such as chronic hepatitis B, AIDS or&#xD;
             tuberculosis.&#xD;
&#xD;
          -  Receiving non-physiological adrenal corticosteroids.&#xD;
&#xD;
          -  Confirmed pituitary and/or hypothalamic malignance by MRI within one year prior to&#xD;
             screening. History or presence of any other malignance disease, any evidence of&#xD;
             present tumor growth.&#xD;
&#xD;
          -  Evidence of congenital intracranial hypertension.&#xD;
&#xD;
          -  Evidence of slipped capital femoral epiphysis.&#xD;
&#xD;
          -  Evidence of scoliosis over 15°.&#xD;
&#xD;
          -  Participation in any other trial of an investigational agent within 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Any other conditions which in the opinion of the investigator precluded enrollment&#xD;
             into the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoyan Yi</last_name>
    <phone>86592-6889121</phone>
    <email>yixiaoyan@amoytop.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College of HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Luo, MD, Ph.D</last_name>
    </contact>
    <contact_backup>
      <last_name>Yan Liang, Ph.D</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth Hormone Deficiency</keyword>
  <keyword>somatropin</keyword>
  <keyword>recombinated human growth hormone</keyword>
  <keyword>Growth Hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

